Login
Navigate Fool.com
Will BSX beat
the market?
Community Rating: 3 Stars: Appealing

13.44 0.09 (0.67%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $13.57
Previous Close $13.35
Daily Range $13.37 - $13.64
52-Week Range $7.07 - $14.08
Market Cap $17.8B
P/E Ratio -148.33
Dividend (Yield) $0.00 (0.0%)
Volume 4,274,015
Average Daily Volume 12,120,139
Current FY EPS $0.78

How do you think BSX
will perform against the market?

Top BSX Bull/Bear Pitches

 

BillZack (10.16)
Submitted June 17, 2010

WAY OVERSOLD AND DUE FOR A GOOD RUN WITH PESSIMISM BEGINING TO ALEVIATE. GOOD PIPELINE OF PRODUCTS.

0 Replies Reply Report this Post
 

lickmyweinie (0)
Submitted September 29, 2010

The simple truth is that competitors have superior products. The management can't dig themselves out of the hole their in. Damage form poor acquisitions and law suits have taken their toll. When ever … More

0 Replies Reply Report this Post

News & Commentary Rss Feed

Can Edwards Lifesciences Corp. Capitalize on This Opportunity?

Edwards wins a legal ruling against Medtronic, but while momentum's behind this stock, don't be overconfident.

U.S. FDA OKs new generation Boston Scientific heart pacing devices

Closing Update: Selling Tied to Ukraine Subsides As Stocks Rebound Off Supports

Abbott Earnings Preview: Emerging Markets & New Products Likely To Drive Sales

S&P 500 Movers: MDT, EW

Investing News: Can These International Expansions Juice Growth?

An approval for Medtronic and a new launch for Boston Scientific could help jump-start sluggish growth in one of the cardiac device industry's most important fields.

Will This Huge New Find Electrify Med Tech's Growth?

Neuromodulation's become a hot growth arena for med tech leaders, but new data from a study could open up even more opportunities in the long run for investors and patients alike.

Has This Once-Hot Med Tech Innovation Flatlined?

Renal denervation, the once-promising treatment for high blood pressure, has fizzled out after a failed trial from Medtronic.

Industry To Closely Follow Upcoming Results Of Medtronic’s Unsuccessful Renal Denervation Trial

St. Jude Sparks Hope for a Pain-Free Future

St. Jude's struggling against rivals Medtronic and Boston Scientific in the neuromodulation space, but its latest approval of its Prodigy device should keep investors looking for more.

See More BSX News...

Sector

Healthcare

Industry

Healthcare Information Services

Boston Scientific Corp. (BSX) Description

The Company develops, manufactures & markets medical devices that are used in interventional cardiology, peripheral interventions, vascular surgery, electrophysiology, neurovascular intervention, oncology, endoscopy, urology, gynecology & neuromodulation. Website: http://www.bsci.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks